Matt Wagoner leads the Global Investigatory Toxicology network for Takeda Pharmaceuticals, where his team applies microphysiological systems (MPS) as predictive and mechanistic tools to help make safer medicines. Before he joined Takeda, Matt led the mRNA safety strategy for AstraZeneca Pharmaceuticals, and worked to develop and deploy MPS tools in support of projects. In the academic arena, Matt co-teaches a drug discovery course at Simmons College in Boston. He received his PhD in Molecular and Cellular Pharmacology from the University of Wisconsin-Madison and bachelors in biochemistry from the University of Illinois Urbana Champaign. In lieu of hobbies, Matt has three kids and the canine equivalent of a frappuchino called a “Woodle.”
Matt will share his experience assessing on- and off-target immunostimulation, which is known to be problematic and difficult to predict preclinically. He will present data on the translation of immune adverse events from preclinical species to the clinic and a new model his team is piloting that incorporates facets of the innate and adaptive immune system in immune drug-induced liver injury in vitro.